Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovey, S M, Brown, S, Doughty, J C, Mallon, E A, Cooke, T G, Edwards, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653773/
https://www.ncbi.nlm.nih.gov/pubmed/19223897
http://dx.doi.org/10.1038/sj.bjc.6604940
_version_ 1782165313704427520
author Tovey, S M
Brown, S
Doughty, J C
Mallon, E A
Cooke, T G
Edwards, J
author_facet Tovey, S M
Brown, S
Doughty, J C
Mallon, E A
Cooke, T G
Edwards, J
author_sort Tovey, S M
collection PubMed
description We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.
format Text
id pubmed-2653773
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26537732010-03-10 Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours Tovey, S M Brown, S Doughty, J C Mallon, E A Cooke, T G Edwards, J Br J Cancer Clinical Study We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab. Nature Publishing Group 2009-03-10 2009-02-17 /pmc/articles/PMC2653773/ /pubmed/19223897 http://dx.doi.org/10.1038/sj.bjc.6604940 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Tovey, S M
Brown, S
Doughty, J C
Mallon, E A
Cooke, T G
Edwards, J
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
title Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
title_full Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
title_fullStr Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
title_full_unstemmed Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
title_short Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
title_sort poor survival outcomes in her2-positive breast cancer patients with low-grade, node-negative tumours
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653773/
https://www.ncbi.nlm.nih.gov/pubmed/19223897
http://dx.doi.org/10.1038/sj.bjc.6604940
work_keys_str_mv AT toveysm poorsurvivaloutcomesinher2positivebreastcancerpatientswithlowgradenodenegativetumours
AT browns poorsurvivaloutcomesinher2positivebreastcancerpatientswithlowgradenodenegativetumours
AT doughtyjc poorsurvivaloutcomesinher2positivebreastcancerpatientswithlowgradenodenegativetumours
AT mallonea poorsurvivaloutcomesinher2positivebreastcancerpatientswithlowgradenodenegativetumours
AT cooketg poorsurvivaloutcomesinher2positivebreastcancerpatientswithlowgradenodenegativetumours
AT edwardsj poorsurvivaloutcomesinher2positivebreastcancerpatientswithlowgradenodenegativetumours

Ejemplares similares